MYOD1 and cancer: In addition, there are molecular differences with ERMS having several distinct driver mutations within the RAS pathway genes and other cancer genes,2 whereas a subset of ssRMSs seem to be more associated with MYOD1 mutations; however, this particular group is evolving as we speak.3,4 Recent studies have made evident that MYOD1 mutations are not restricted to FN-RMS with spindle cell morphology,2 supporting the need for better risk stratification beyond MYOD1 and RAS mutation status.